ClinicalTrials.gg
Not yet recruitingNCT07483632VOYAGEUpdated Mar 19, 2026

A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

A Phase 3 interventional study of Diroximel Fumarate and Dimethyl Fumarate in Relapsing Forms of Multiple Sclerosis, sponsored by Biogen. Not yet recruiting. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. Dimethyl Fumarate · Multiple Sclerosis.

Planned enrollment
9th of 22
185 · median 86
Started
2026
the only one that year
Phase 3
9 of 22
1 open now
Registered
22nd of 22
by date
Lead sponsor
17 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 9 in phase 3, and was the 22nd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis is open now.

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the study drugs diroximel fumarate (DRF) and dimethyl fumarate (DMF) in children with MS who may be experiencing relapses.

Participants will be divided into 2 groups based on their weight:

  • Group A will include children who weigh 40 kilograms (kg) or less. They will receive DRF in both Part 1 and Part 2 of the study.
  • Group B will include children who weigh more than 40 kg. They will be randomly assigned to receive DRF, DMF, or fingolimod. Fingolimod is a drug already used to treat MS in adults. In Part 2, they will receive DRF.

This is a 2-part study. Part 1 treatment will last 96 weeks. Participants who complete Part 1 may move to Part 2. Part 2 is an extension period. Treatment will last another 96 weeks and will help researchers learn about the long-term safety and effects of treatment.

The main goal of the study is to learn about the safety of DRF and DMF and compare their effect on relapses and brain lesions with fingolimod.

The main questions researchers want to answer are:

  • How many participants have adverse events and serious adverse events?
  • How often do participants relapse after treatment with DRF and DMF compared to fingolimod?

Researchers will take brain imaging scans to check for any new areas of brain inflammation and compare the brain lesions before and after treatment.

Researchers will also measure the amount of drug in the blood to understand how the body processes it. To check safety, they will monitor participants' growth and development, and compare changes in heart tests, vital signs, and lab tests. They will also use rating scales to monitor depression symptoms.

The study will be done as follows:

Part 1 (Treatment Period)

  • After screening, participants will join Part 1 and be divided into 2 groups based on their weight.
  • Participants in Group A will receive DRF.
  • Participants in Group B will be randomly assigned to receive either DRF, DMF, or fingolimod.
  • Neither the researchers nor the participants will know which drug or dose the participants will receive in Group B. Participants in Group B will also receive a placebo so they do not know which drug is being given. A placebo looks like a study drug but contains no real medicine.
  • All study drugs will be taken by mouth, once or twice a day. Participants who take DRF or DMF will start with a lower dose during the 1st week, then move to a standard dose.
  • Treatment in Part 1 will last for 96 weeks. Participants will have up to 11 study visits and 7 phone calls.
  • Participants who do not move onto Part 2 will also have a safety follow-up period of 4 to 8 weeks. This will include 1 study visit and 1 phone call.
  • The total length of Part 1, including the screening, treatment, and follow-up, will be up to 108 weeks.

Part 2 (Extension Period)

  • Participants who complete Part 1 can move on to Part 2 of the study.
  • All participants in Part 2 will receive DRF by mouth for 96 weeks.
  • Participants will have up to 10 more study visits and 1 telephone call during treatment.
  • They will also have a 4-week safety follow-up, including 1 study visit and 1 phone call.
  • The total length of Part 2 will be up to 100 weeks.
Read the detailed description

The primary objectives of this study are to evaluate the safety, tolerability of diroximel fumarate (DRF), the noninferiority of the clinical efficacy of monomethyl fumarate (MMF) (pooled DRF and dimethyl fumarate [DMF] treatment) compared to that of fingolimod and long-term safety and tolerability of DRF in participants who completed Week 96 of the Treatment Period. The secondary objectives of this study are to characterize the pharmacokinetic (PK) profile of DRF metabolites (MMF and 2-hydroxyethyl succinimide [HES]), additional safety and tolerability of DRF, noninferiority of the radiological efficacy of MMF (pooled DRF and DMF treatment) compared to that of fingolimod, and to further describe the safety and long-term multiple sclerosis (MS) outcomes of DRF in participants who completed Week 96 of the Treatment Period.

03

Conditions studied

  • Relapsing Forms of Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Treatment Period:

  • Must have a diagnosis of pediatric MS (as defined by the revised consensus definition of pediatric MS).
  • Must have an Expanded Disability Status Scale (EDSS) score between 0 and 5.0, inclusive.
  • Must have experienced at least 1 of the following conditions:

    1. greater than or equal to 1 relapse in the 12 months prior to the Baseline Visit (Day 1),
    2. greater than or equal to 2 relapses in the 24 months prior to the Baseline Visit (Day 1), or
    3. evidence of gadolinium (Gd)-enhancing lesions of the brain on magnetic resonance imaging (MRI) within 6 months prior to the Baseline Visit (Day 1).
  • Participants must be neurologically stable with no evidence of relapse within 30 days prior to the Baseline Visit (Day 1).

Open-Label Extension Period:

- Participants who completed the study treatment in Cohorts A or B through the Week 96 Visit.

Key Exclusion Criteria

Treatment Period:

  • History of progressive MS.
  • History of disorders mimicking MS, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis and neuromyelitis optical spectrum disorder), systemic disorders (e.g., Sjögren's disease and lupus erythematosus), metabolic disorders (e.g., dystrophies), and infectious disorders.
  • History of severe allergic or anaphylactic reactions or any allergic reactions that in the opinion of the Investigator are likely to be exacerbated by any component of the study treatment.
  • History of, or ongoing, malignant disease, including solid tumors, skin , and hematologic malignancies.
  • History of gastrointestinal (GI) surgery (except appendectomy or cholecystectomy that occurred more than 6 months prior to the Screening Visit), inflammatory bowel disease (Crohn's disease, ulcerative colitis), or another and active GI condition at the Investigator's discretion.
  • Known to fumaric acid derivatives or any of DRF or DMF.
  • Diagnosis of macular edema prior to randomization.

Open-Label Extension Period:

  • Any significant changes in medical history occurring after enrollment in the Treatment Period, including laboratory test abnormalities or current clinically significant conditions that, in the opinion of the Investigator, would have excluded the participant's participation in the Treatment Period. The Investigator must reassess the participant's medical fitness for participation and consider any factors that would preclude treatment.
  • Participants who discontinued study treatment due to tolerability issues.
  • Other unspecified reasons that, in the opinion of the Investigator or the Sponsor, make the participant unsuitable for participation in the OLE Period.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
185 participants (estimated)

Study arms

  • Experimental
    TP Cohort A

    Participants weighing ≤ 40 kilograms (kg) will receive DRF 231 milligrams (mg) orally, once daily (QD) (starting dose) on Days 1 to 7 followed by DRF 231 mg orally, BID (twice daily) (maintenance dose) on Day 8 through Week 96.

    Drug: Diroximel Fumarate

  • Experimental
    TP Cohort B: Sub-cohort 1: DRF

    Participants weighing \>40 kg will receive DRF/placebo matching fingolimod 231 mg orally, BID (starting dose) on Days 1 to 7 followed by DRF 462 mg orally, BID (maintenance dose) on Day 8 through Week 96.

    Drug: Diroximel Fumarate · Drug: Placebo matching fingolimod

  • Experimental
    TP Cohort B: Sub-cohort 1: Fingolimod

    Participants weighing \>40 kg will receive Fingolimod 0.5 mg orally, QD followed by placebo matching DRF 231 mg (starting dose) orally, BID on Days 1 to 7 followed by placebo matching DRF 462 mg (maintenance dose) orally, BID on Day 8 through Week 96.

    Drug: Fingolimod · Drug: Placebo matching DRF

  • Experimental
    TP Cohort B: Sub-cohort 2: DMF

    Participants weighing \>40 kg will receive DMF/placebo matching fingolimod 120 mg (starting dose) orally, BID on Days 1 to 7 followed by DMF 240 mg (maintenance dose) orally BID, on Day 8 through Week 96.

    Drug: Dimethyl Fumarate · Drug: Placebo matching fingolimod

  • Experimental
    TP Cohort B: Sub-cohort 2: Fingolimod

    Participants weighing \>40 kg will receive Fingolimod 0.5 mg oral QD followed by placebo matching DMF 120 mg (starting dose) orally, BID on Days 1 to 7 followed by placebo matching DMF 240 mg (maintenance dose) orally, BID through Week 96.

    Drug: Fingolimod · Drug: Placebo matching DMF

  • Experimental
    Open-label Extension (OLE) Period: Participants from Cohort A

    Participants from Cohort A weighing ≤ 40 kg will receive DRF 231 mg orally, BID and participants weighing \>40 kg will receive DRF 462 mg orally, BID up to 192 weeks.

    Drug: Diroximel Fumarate

  • Experimental
    OLE Period: Participants from Cohort B

    Participants from Cohort B will receive DRF 231 mg orally, BID for 7 days, followed by the maintenance dose of DRF 462 mg orally, BID up to 192 weeks.

    Drug: Diroximel Fumarate

Interventions

  • Oral capsule

    Also known as: Vumerity, BIIB098, ALK8700

  • Oral capsule

    Also known as: Tecfidera, BG00012

  • Oral capsule

    Also known as: Gilenya

  • DrugPlacebo matching DRF

    Oral capsule

  • DrugPlacebo matching DMF

    Oral capsule

  • DrugPlacebo matching fingolimod

    Oral capsule

06

What researchers measure

Primary outcomes

  1. TP Cohort A and OLE Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation

    Time frame: Cohort A: From first dose of study drug up to end of follow-up (up to Week 104), OLE: Baseline (Week 96) up to the end of OLE period (up to Week 196)

  2. TP Cohort B: Annualized Relapse Rate (ARR) Through Week 96

    Time frame: Baseline (Day 1) up to Week 96

Secondary outcomes

  1. TP Cohorts A and B: Maximum Observed Concentration at Steady State (Cmax,ss) of Monomethyl Fumarate (MMF)

    Time frame: Predose and at multiple timepoints post dose up to Week 96

  2. TP Cohorts A and B: Minimum Observed Concentration at Steady State (Cmin,ss) of MMF

    Time frame: Predose and at multiple timepoints post dose up to Week 96

  3. TP Cohorts A and B: Cmax,ss of 2-Hydroxyethyl Succinimide (HES)

    Time frame: Predose and at multiple timepoints post dose up to Week 96

  4. TP Cohorts A and B: Cmin,ss of HES

    Time frame: Predose and at multiple timepoints post dose up to Week 96

  5. TP Cohorts A, B and OLE Period: Number of Participants with Potentially Clinically Serious (PCS) Change from Baseline in Vital Sign Parameters

    Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196

  6. TP Cohorts A, B and OLE Period: Number of Participants With Change From Baseline in Clinically Relevant Electrocardiogram (ECG) Abnormalities

    Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196

  7. TP Cohorts A, B and OLE Period: Number of Participants with PCS Change from Baseline in Clinical Laboratory Parameters

    Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196

  8. TP Cohorts A, B and OLE Period: Change From Baseline in Height

    Time frame: Cohorts A and B: Baseline up to Week 104, OLE: Baseline (Week 96) up to Week 196

  9. TP Cohorts A, B and OLE Period: Change From Baseline in Weight

    Time frame: Cohorts A and B: Baseline up to Week 104, OLE: Baseline (Week 96) up to Week 196

  10. TP Cohorts A, B and OLE Period: Change From Baseline in Tanner Score

    Assessment of Tanner stage will be performed by a healthcare professional experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected for all male participants with bone age \< 16 years and for female participants who are premenarche and have a bone age of \< 16 years and will be stopped once the participant's bone age reaches ≥ 16 years or once the participant is postmenarche.

    Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196

  11. TP Cohorts A, B and OLE Period: Change From Baseline in Bone Age

    Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196

  12. TP Cohorts A, B and OLE Period: Number of Participants with Change From Baseline in Endocrine Tests

    Endocrine parameters to be tested will include insulin-like growth factor 1, and insulin-like growth factor binding protein for both females and males; follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E-2) for females; and testosterone, FSH, and LH for males. All endocrine tests will stop being performed once the participant has reached a bone age of ≥ 16 years or the participant is postmenarche.

    Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196

  13. TP Cohorts A, B and OLE Period: Change From Baseline in Depression Monitored Using the Children's Depression Rating Scale for Participants <18 Years or the Hamilton Rating Scale for Depression (HAMD-17) for Participants ≥18 Years

    Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196

  14. TP Cohorts A, B and OLE Period: Change From Baseline in Depression Monitored Using the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assesses whether participant experiences any of the following 1. completed suicide, 2. suicide attempt (response of "yes" on "actual attempt"), 3. preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4. any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 5. self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

    Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196

  15. TP Cohort B: Change From Baseline in Annualized Rate of New/Newly Enlarging (N/NE) T2 Hyperintense Lesions Through Week 96

    Time frame: Baseline (Day 1) up to Week 96

  16. TP Cohort B: Time to First Relapse

    Time frame: Baseline (Day 1) up to Week 96

  17. TP Cohort B: Percentage of Participants Free of Relapse up to Week 96

    Time frame: Baseline (Day 1) up to Week 96

  18. TP Cohort B and OLE Period: Change From Baseline in Expanded Disability Status Scale (EDSS) Score

    The EDSS is a method of quantifying disability and monitoring changes in the level of disability over time. EDSS score ranges from 0 (normal neurological exam) to 10 (death from MS) with higher scores indicating more disability.

    Time frame: Cohort B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196

  19. TP Cohort B: Change From Baseline in Number of N/NE T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans at Weeks 48 and 96

    Time frame: Baseline up to Weeks 48 and 96

  20. TP Cohort B: Number of Gadolinium (Gd)-Enhancing Lesions on Brain MRI Scans at Baseline and at Weeks 48 and 96

    Time frame: At Baseline, Weeks 48 and 96

  21. TP Cohort B: Number of Participants With T1 Hypointense Lesions at Week 96

    Time frame: At Week 96

  22. TP Cohort B: Change From Baseline in Percentage of Participants Free of N/NE T2 Hyperintense Lesions on Brain MRI Scans at Weeks 24, 48, and 96

    Time frame: Baseline up to Weeks 24, 48, and 96

  23. TP Cohort B: Change From Baseline in Percentage of Participants Free of New MRI Activity at Weeks 24, 48, and 96

    Free of new MRI activity is defined as free of Gd-enhancing lesions and free of N/NE T2 MRI lesions on brain MRI scans.

    Time frame: Baseline up to Weeks 24, 48, and 96

  24. TP Cohort B: Number of Participants With TEAEs, SAEs and AEs Leading to Treatment Discontinuation

    Time frame: From first dose of study drug up to end of follow-up (up to Week 104)

  25. OLE Period: ARR at Weeks 144 and 192

    Time frame: At Weeks 144 and 192

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2034, 92 months later.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 92 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 19, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Jul 28, 2034
CompletionEst.
Jun 19, 2035
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07483632
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Jul 28, 2034 (estimated)
Completion
Jun 19, 2035 (estimated)
Last update
Mar 19, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Diroximel fumarate · Dimethyl Fumarate · Fingolimod

Start the discussion